CHENNAI MEENAKSHI MULTISPECIAL is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 31 | 28 | 38 | 35 | 37 |
| EBITDA (ex other income) | 6 | 3 | 2 | (0) | (0) |
| margin % | 18.2 | 10.1 | 4.5 | (0.6) | (0.7) |
| Owners' profit | 4 | 1 | (0) | (1) | (1) |
| EPS, as reported (₹) | 5.32 | 1.19 | (0.57) | 1.84 | 1.50 |
| ROE % · ROCE % | (514.0) · 46.7 | 732.3 · 18.6 | 130.5 · 8.4 | 72.8 · (5.0) | 36.3 · (2.8) |
| Debt / equity (x) | (13.68) | 87.39 | (34.86) | (5.63) | (3.46) |
| Cash from operations | 4 | 3 | 2 | 2 | 0 |
| Capex | (2) | (1) | (2) | (0) | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 10 |
| Profit before tax | (0) | (1) | (1) | 0 | (1) | 0 | (1) | (0) |
| Net profit | (0) | (1) | (1) | 0 | (1) | 0 | (1) | (0) |
| EPS (₹) | (0.51) | (0.90) | (0.84) | 0.42 | 0.99 | 0.20 | 0.72 | 0.03 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · 36th AGM on Sep 30 via video conferencing, book closure Sep 24-30 | compliance | minimal | — | — |
| 8 Sept 2026 · Record date set at Sep 23, 2026 for 36th AGM e-voting eligibility | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Register Closure Set for 36th AGM on September 30, 2026 | compliance | minimal | — | — |
| 8 Sept 2026 · 36th Annual Report and AGM Notice for FY 2025-26 submitted | board shareholder meetings | low | — | — |
| 8 Sept 2026 · 36th AGM notice - Sep 30, 2026 via VC; reappoints MD, adds directors | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Board approves MD re-appointment, redesignates 2 independent directors | management changes | medium | — | — |
| 1 Sept 2026 · Board re-designates two Independent Directors as Non-Independent | management changes | medium | — | — |
| 27 Aug 2026 · Board Meeting rescheduled to September 1, 2026 | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Board meeting on 28 Aug 2026 to fix 36th AGM date and book closure | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 33.9 |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.6 | 23.2 | 12 of 29 | 61% |
| ROCE | (12.7) | 6.1 | 26 of 29 | 11% |
| ROE | 36.3 | 7.3 | 3 of 26 | 92% |
| Debt / Equity | (3.5) | 0.0 | 1 of 26 | 100% |
| EBITDA margin | 4.9 | 25.6 | 18 of 24 | 26% |
| Revenue growth | 7.0 | 20.8 | 20 of 25 | 21% |
| Profit growth | (106.8) | 22.0 | 22 of 25 | 13% |
| Market cap | 28 | 38 | 19 of 30 | 38% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
